TISIDB

Summary
Symbol	UGP2
Name	UDP-glucose pyrophosphorylase 2
Aliases	UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location	2p14-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm
Domain	PF01704 UTP--glucose-1-phosphate uridylyltransferase
Function	Plays a central role as a glucosyl donor in cellular metabolic pathways.

> Gene Ontology [ TOP ]
Biological Process	GO:0000271 polysaccharide biosynthetic process GO:0005976 polysaccharide metabolic process GO:0005977 glycogen metabolic process GO:0005978 glycogen biosynthetic process GO:0006011 UDP-glucose metabolic process GO:0006065 UDP-glucuronate biosynthetic process GO:0006073 cellular glucan metabolic process GO:0006091 generation of precursor metabolites and energy GO:0006112 energy reserve metabolic process GO:0009225 nucleotide-sugar metabolic process GO:0009226 nucleotide-sugar biosynthetic process GO:0009250 glucan biosynthetic process GO:0015980 energy derivation by oxidation of organic compounds GO:0016051 carbohydrate biosynthetic process GO:0019255 glucose 1-phosphate metabolic process GO:0033692 cellular polysaccharide biosynthetic process GO:0034637 cellular carbohydrate biosynthetic process GO:0044042 glucan metabolic process GO:0044262 cellular carbohydrate metabolic process GO:0044264 cellular polysaccharide metabolic process GO:0044723 single-organism carbohydrate metabolic process GO:0046398 UDP-glucuronate metabolic process
Molecular Function	GO:0003983 UTP:glucose-1-phosphate uridylyltransferase activity GO:0005536 glucose binding GO:0016779 nucleotidyltransferase activity GO:0019103 pyrimidine nucleotide binding GO:0030246 carbohydrate binding GO:0032557 pyrimidine ribonucleotide binding GO:0048029 monosaccharide binding GO:0051748 UTP-monosaccharide-1-phosphate uridylyltransferase activity GO:0070569 uridylyltransferase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00040 Pentose and glucuronate interconversions hsa00052 Galactose metabolism hsa00500 Starch and sucrose metabolism hsa00520 Amino sugar and nucleotide sugar metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-211859: Biological oxidations R-HSA-173599: Formation of the active cofactor, UDP-glucuronate R-HSA-70326: Glucose metabolism R-HSA-156588: Glucuronidation R-HSA-3322077: Glycogen synthesis R-HSA-1430728: Metabolism R-HSA-71387: Metabolism of carbohydrates R-HSA-156580: Phase II conjugation

Summary
Symbol	UGP2
Name	UDP-glucose pyrophosphorylase 2
Aliases	UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location	2p14-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between UGP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	UGP2
Name	UDP-glucose pyrophosphorylase 2
Aliases	UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location	2p14-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of UGP2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -2.45; FDR: 0.04150	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	UGP2
Name	UDP-glucose pyrophosphorylase 2
Aliases	UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location	2p14-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of UGP2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.003	0.993
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.309	0.906
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.222	0.907
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.077	0.828
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.406	0.846
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.343	0.9
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.167	0.737
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.443	0.823
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.21	0.927
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.002	0.999
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.571	0.854
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.03	0.603

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of UGP2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	UGP2
Name	UDP-glucose pyrophosphorylase 2
Aliases	UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location	2p14-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UGP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	UGP2
Name	UDP-glucose pyrophosphorylase 2
Aliases	UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location	2p14-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UGP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UGP2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	UGP2
Name	UDP-glucose pyrophosphorylase 2
Aliases	UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location	2p14-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UGP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	UGP2
Name	UDP-glucose pyrophosphorylase 2
Aliases	UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location	2p14-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of UGP2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	UGP2
Name	UDP-glucose pyrophosphorylase 2
Aliases	UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location	2p14-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between UGP2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	UGP2
Name	UDP-glucose pyrophosphorylase 2
Aliases	UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location	2p14-p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting UGP2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse UGP2